全文获取类型
收费全文 | 388篇 |
免费 | 18篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 17篇 |
妇产科学 | 8篇 |
基础医学 | 44篇 |
口腔科学 | 44篇 |
临床医学 | 35篇 |
内科学 | 46篇 |
皮肤病学 | 3篇 |
神经病学 | 22篇 |
特种医学 | 14篇 |
外科学 | 39篇 |
综合类 | 17篇 |
预防医学 | 45篇 |
眼科学 | 22篇 |
药学 | 15篇 |
中国医学 | 2篇 |
肿瘤学 | 34篇 |
出版年
2024年 | 1篇 |
2023年 | 6篇 |
2022年 | 10篇 |
2021年 | 21篇 |
2020年 | 10篇 |
2019年 | 15篇 |
2018年 | 21篇 |
2017年 | 19篇 |
2016年 | 7篇 |
2015年 | 15篇 |
2014年 | 19篇 |
2013年 | 13篇 |
2012年 | 29篇 |
2011年 | 34篇 |
2010年 | 12篇 |
2009年 | 12篇 |
2008年 | 24篇 |
2007年 | 20篇 |
2006年 | 23篇 |
2005年 | 13篇 |
2004年 | 12篇 |
2003年 | 5篇 |
2002年 | 9篇 |
2001年 | 5篇 |
2000年 | 6篇 |
1999年 | 1篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1992年 | 3篇 |
1991年 | 7篇 |
1990年 | 4篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 2篇 |
1985年 | 4篇 |
1984年 | 4篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1979年 | 2篇 |
1975年 | 1篇 |
排序方式: 共有408条查询结果,搜索用时 15 毫秒
81.
The reasons underlying the need for extraction of 2765 permanent teeth carried out over a 6 month period in the Out-patient Clinic in the Dental Faculty, University of Malaya, was investigated. The present study showed that dental caries (67.4%) is the leading cause for extraction followed by periodontal disease (19.6%). Caries accounted for the highest proportion of extractions up to the age of 50 whereas periodontal disease becomes the major factor beyond this age. The highest frequency of extractions carried out was between the ages of 21-30. 相似文献
82.
83.
There are several reports of beneficial effects of ACE inhibitors in both primary and secondary pulmonary hypertension. However the effect of ACE inhibitors in mitral stenosis is not documented. The authors report three patients with severe mitral stenosis in whom surgery was delayed. They had initial symptomatic improvement with diuretics and sodium restriction, but had recurrence of their symptoms while on treatment. Enalapril not only relieved their symptoms in particular exertional dyspnoea and haemoptysis but prevented recurrence and improved their effort tolerance without causing excessive fall of blood pressure or impairment of renal function. 相似文献
84.
85.
86.
Peter A Dargaville Beverley Copnell John F Mills Ismail Haron Jimmy KF Lee David G Tingay Jaafar Rohana Lindsay F Mildenhall Mei‐Jy Jeng Anushree Narayanan Malcolm R Battin Carl A Kuschel Joel L Sadowsky Harshad Patel Charles J Kilburn John B Carlin Colin J Morley 《Acta paediatrica (Oslo, Norway : 1992)》2013,102(2):e90-e93
87.
88.
89.
A cluster randomized trial on improving nurses’ detection and management of elder abuse and neglect (I‐NEED): study protocol 下载免费PDF全文
Debbie Ann Loh MMedSci Wan Yuen Choo MMedSc MAppStats PhD Noran Naqiah Hairi MBBS MPH PhD Sajaratulnisah Othman MBBS MFamMed PhD Farizah Mohd Hairi MBBS MPH DSc Fadzilah Hanum Mohd Mydin MBBS MFamMed Siti Nur Illiani Jaafar MNSc RN Maw Pin Tan MD MBBS MRCP Zainudin Mohd Ali MD MPH MPH Suriyati Abdul Aziz MD MPH Rohaya Ramli MD MPH Rosmala Mohamad MD Zaiton Lal Mohammad MBBS MPH Norlela Hassan RN Patricia Brownell MSW PhD Awang Bulgiba MBBS MMed PhD 《Journal of advanced nursing》2015,71(11):2661-2672
90.
Laurent Mathiot Guillaume Herbreteau Simon Robin Charlotte Fenat Jaafar Bennouna Christophe Blanquart Marc Denis Elvire Pons-Tostivint 《Current oncology (Toronto, Ont.)》2022,29(5):3748
Introduction: Assessment of actionable gene mutations and oncogene fusions have made a paradigm shift in treatment strategies of non-small cell lung cancer (NSCLC). HRAS mutations involved around 0.2–0.8% of NSCLC patients, mostly on codon 61. For these patients, few data are available regarding clinical characteristics and response to therapies. Methods: Next-Generation Sequencing (NGS) done routinely at Nantes University Hospital was used to identify HRAS molecular alterations in NSCLC patients. We identified and described four HRAS p.GlnQ61Leu mutated patients. Literature of previously HRAS-mutant NSCLC cases was reviewed, and available data in solid tumour with the most advanced H-Ras specific inhibitor, tipifarnib, were presented. Results: Of 1614 patients diagnosed with advanced NSCLC from January 2018 to December 2020, four (0.25%) had HRAS p.Gln61Leu mutation. Three of them died during the first-line systemic therapy. Furthermore, three additional cases were identified in literature. All cases were current or former smokers, most of them had pleural or pericardial effusion at diagnosis. Conclusions: The clinical course of patients with HRAS-mutant NSCLC remains unclear. Furthers cases should be identified in order to clarify prognosis and response to therapies. Tipifarnib, a farnesyl transferase inhibitor, is a promising candidate to target HRAS-mutant tumours and should be explored in NSCLC patients. 相似文献